Barclays
SYRE icon

Barclays’s Spyre Therapeutics SYRE Stock Holding History

Barclays’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.35M Buy
94,069
+48,283
+105% +$3.52M ﹤0.01% 1565
2026
Q1 		$2.31M Sell
45,786
-136,738
-75% -$5.16M ﹤0.01% 2260
2025
Q4 		$5.98M Buy
182,524
+14,194
+8% +$371K ﹤0.01% 2070
2025
Q3 		$2.82M Sell
168,330
-48,316
-22% -$788K ﹤0.01% 2610
2025
Q2 		$3.24M Buy
216,646
+2,040
+1% +$30.2K ﹤0.01% 2475
2025
Q1 		$3.46M Buy
214,606
+91,535
+74% +$1.9M ﹤0.01% 2203
2024
Q4 		$2.87M Buy
123,071
+17,604
+17% +$516K ﹤0.01% 2620
2024
Q3 		$3.1M Buy
105,467
+41,424
+65% +$1.15M ﹤0.01% 2488
2024
Q2 		$1.51M Buy
64,043
+18,081
+39% +$610K ﹤0.01% 2339
2024
Q1 		$1.74M Buy
45,962
+464
+1% +$13.4K ﹤0.01% 2689
2023
Q4 		$979K Buy
+45,498
New +$627K ﹤0.01% 3446
2023
Q3 		– Sell
-4
Closed -$45 – 4703
2023
Q2 		$45 Hold
4
– – ﹤0.01% 4466
2023
Q1 		$29 Hold
4
– – ﹤0.01% 5019
2022
Q4 		$45 Hold
4
– – ﹤0.01% 5217
2022
Q3 		$0 Hold
4
– – ﹤0.01% 5128
2022
Q2 		$0 Sell
4
-262
-98% -$9.18K ﹤0.01% 5259
2022
Q1 		$16K Sell
266
-1,700
-86% -$143K ﹤0.01% 4508
2021
Q4 		$233K Buy
1,966
+1,305
+197% +$206K ﹤0.01% 3510
2021
Q3 		$131K Buy
661
+434
+191% +$75.9K ﹤0.01% 3795
2021
Q2 		$40K Sell
227
-1,291
-85% -$235K ﹤0.01% 4235
2021
Q1 		$301K Buy
1,518
+929
+158% +$178K ﹤0.01% 3498
2020
Q4 		$116K Sell
589
-196
-25% -$40.6K ﹤0.01% 4069
2020
Q3 		$139K Sell
785
-140
-15% -$25.9K ﹤0.01% 4064
2020
Q2 		$213K Buy
925
+578
+167% +$110K ﹤0.01% 4023
2020
Q1 		$41K Sell
347
-712
-67% -$121K ﹤0.01% 5347
2019
Q4 		$202K Buy
1,059
+514
+94% +$101K ﹤0.01% 5022
2019
Q3 		$105K Sell
545
-143
-21% -$27.9K ﹤0.01% 5446
2019
Q2 		$118K Buy
688
+189
+38% +$32.7K ﹤0.01% 5568
2019
Q1 		$100K Buy
+499
New +$104K ﹤0.01% 5362
2018
Q4 		– Sell
-245
Closed -$59K – 7310
2018
Q3 		$59K Buy
245
+197
+410% +$46K ﹤0.01% 5976
2018
Q2 		$13K Sell
48
-80
-63% -$19.7K ﹤0.01% 6420
2018
Q1 		$32K Buy
+128
New +$23.1K ﹤0.01% 6209

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Barclays's SYRE Position: Q2 2026 in Review

Barclays increased its Spyre Therapeutics (SYRE) stake by 105% in Q2 2026, buying an estimated $3.52M and bringing the position to 94,069 shares worth $8.35M. The position accounts for ﹤0.01% of the portfolio, ranked #1565.

Barclays first reported a position in SYRE in Q1 2018 and has held it in 32 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Barclays held 94,069 shares of Spyre Therapeutics worth $8.35M as of Q2 2026.
  • Barclays bought 48,283 Spyre Therapeutics shares in Q2 2026, an estimated $3.52M.
  • Spyre Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1565 holding.
  • Barclays first reported a position in Spyre Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.